Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Uganda agrees deal with the US to take deported migrants. How Zambia plans to tackle a violent gold rush. And why are gulper sharks under threat off Somalia’s Puntland state Show more Uganda agrees a ...

Developer Hadley Property Group has lodged a hybrid planning application to redevelop the flagship former GlaxoSmithKline ...

The company said the vaccine, called Z-1018, which was tested in patients aged 50 to 69 years, demonstrated similar antibody and T cell responses to those produced by GSK's Shingrix and had a ...

On May 12, Trump signed an executive order stating that U.S. consumers are being overcharged for prescription drugs and that “Americans must therefore have access to the most-favored-nation price.” ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Before her new role as Head of Marketing for India, Sri Lanka & Bangladesh, she worked at DBS Bank as SVP Marketing, after a decade at J. Walter Thompson.

JAZZ Pharmaceuticals JAZZ announced that it has signed an agreement with Denmark-based biopharmaceutical company Saniona to acquire worldwide rights to the latter’s investigational epilepsy drug, ...

A seasoned finance executive, Paul brings more than 20 years of international experience across diverse sectors to Dulsco Group ...